Hoda Salem | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Hoda Salem | Clinical Trials | Best Researcher Award

Prof. Dr. Hoda Salem, University of Tabuk, Saudi Arabia

Prof. Dr. Hoda Salem 🎓 is a distinguished clinical pharmacy expert with a Ph.D. in Pharmaceutical Sciences from Tanta University, Egypt 🇪🇬. With over two decades of academic and clinical experience, she currently serves as Professor at Tabuk University, Saudi Arabia 🇸🇦. She has led numerous funded research projects, particularly in neuropharmacology and pharmacogenetics 🧬🧠. A prolific scholar, Dr. Salem has published in Q1 journals 📚 and actively mentors Ph.D. and MSc students. Her contributions extend to curriculum development, hospital training, and quality assurance in education 🌍. She’s a driving force in pharmacy education and clinical research excellence.

Publication Profile

Google Scholar

Education

Prof. Dr. Hoda Salem 🎓 earned her Bachelor’s degree in Pharmaceutical Sciences from Tanta University, Egypt 🇪🇬. She continued her academic journey with a Master’s degree (M.Sc.) in Clinical Pharmacy from the same university, demonstrating early on her commitment to specialized healthcare and pharmaceutical practice 💊. Her pursuit of excellence culminated in a Ph.D. in Clinical Pharmacy in 2008 🧪, also from Tanta University. This strong academic foundation laid the groundwork for her impactful career in clinical pharmacy, education, and research, making her a respected figure in both Egyptian and international pharmaceutical education and clinical advancement.

Experience

Prof. Dr. Hoda Salem ⚕️ has made significant contributions to both scientific and clinical work in pharmacy education and healthcare. She played a pivotal role in quality assurance and accreditation by leading the self-study efforts and contributing to strategic planning at Tabuk and Al-Azhar Universities 📊📚. As a committee member, she helped supervise undergraduate examinations and mentored numerous Ph.D. and M.Sc. research projects 🎓🧬. Her clinical work includes patient counseling, drug dispensing, and providing accurate drug information to healthcare professionals at Tanta University Hospitals 💊🏥, reinforcing her commitment to enhancing both education and patient care.

Research Focus

Prof. Dr. Hoda Salem’s 🧪 research focus lies in clinical pharmacy, pharmaceutics, and neuropharmacology with a multidisciplinary approach integrating nanotechnology, drug delivery systems, and natural compounds. Her publications explore the treatment of diseases such as Alzheimer’s 🧠, Parkinson’s, ADHD, and fungal infections, along with oncology 🧬 and pharmacogenetics in breast cancer therapy. She has also worked on innovative therapies like solid lipid nanoparticles, niosomal gels, and bone marrow stem cell applications. Her clinical trials and lab studies reflect a deep commitment to therapeutic innovation, patient care, and translational research 💊🔬, bridging pharmaceutical science and clinical outcomes for better healthcare.

Publication Top Notes

Fluconazole-loaded solid lipid nanoparticles topical gel for treatment of pityriasis versicolor: formulation and clinical study‏

Neuroprotective effects of phytochemicals against aluminum chloride-induced Alzheimer’s disease through ApoE4/LRP1, wnt3/β-catenin/gsk3β, and TLR4/NLRP3 pathways with physical …‏

Neuroprotective effect of morin hydrate against attention-deficit/hyperactivity disorder (ADHD) induced by MSG and/or protein malnutrition in rat pups: Effect on oxidative …‏

Autologous transplantation of CD34+ bone marrow derived mononuclear cells in management of non-reconstructable critical lower limb ischemia‏

A randomized controlled trial evaluating the effects of amlodipine on myocardial iron deposition in pediatric patients with thalassemia major‏

The role of hepatic expression of STAT1, SOCS3 and PIAS1 in the response of chronic hepatitis C patients to therapy‏

Enhancement of zaleplon oral bioavailability using optimized self-nano emulsifying drug delivery systems and its effect on sleep quality among a sample of psychiatric patients‏

Effective method of evaluating myocardial iron concentration in pediatric patients with thalassemia major‏

Formulation, in-vitro and in-vivo evaluation of nystatin topical gel‏

DEVELOPMENT AND CLINICAL EVALUATION OF TOPICAL HYDROQUINONE NIOSOMAL GEL FORMULATION FOR THE TREATMENT OF MELASMA‏

Effect of oral Methyl Prednisolone on different radiological patterns of hypersensitivity pneumonitis‏

Surya Nandan Meena | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Surya Nandan Meena | Drug Discovery and Development | Best Researcher Award

Dr. Surya Nandan Meena, Savitribai Phule Pune University, India

Dr. Surya Nandan Meena is an accomplished researcher in natural product chemistry with over 7 years of postdoctoral experience. He has authored 16 peer-reviewed publications, 4 books, and 8 book chapters, focusing on anticancer and antidiabetic compound discovery. 🧬 His expertise spans LC-MS/MS, molecular docking, and mammalian cell assays. 🎓 A recipient of prestigious fellowships like the Dr. D.S. Kothari and SERB-DST, he has led international projects, mentored students, and contributed to multidisciplinary science globally. 🌱 Passionate about drug discovery and marine biotechnology, Dr. Meena actively serves on editorial boards and scientific societies worldwide.

Publication Profile

Google Scholar

Education

Dr. Surya Nandan Meena is a dedicated scholar with a robust academic background in biotechnology and agriculture. He earned his Ph.D. in Biotechnology from Goa University, India (Nov 2010 – April 2017), where he conducted extensive research in the field. Prior to that, he completed his M.Sc. in Plant Biotechnology from UAS Dharwad, India (July 2006 – April 2009), further refining his expertise in plant sciences 🌿. His academic journey began with a B.Sc. (Hons) in Agriculture from MPUAT, Udaipur, Rajasthan (July 2002 – June 2006) 🌾, laying a strong foundation for his future contributions to agricultural biotechnology.

Awards

Dr. Surya Nandan Meena has been honored with numerous prestigious awards and research fellowships throughout his academic journey. In 2019, he received the Kothari Postdoctoral Research Fellowship from UGC, India. He earned the Best Research Paper Appreciation Award from Anchrome Pvt. Ltd. in 2018 📜. In 2017, he was awarded the National Postdoctoral Fellowship by SERB-DST, India. His dedication was also recognized with the Senior Research Fellowship from DBT in 2013 and the Best Poster Presentation Award in 2012 🧪. Earlier, he secured the Junior Research Fellowship from DBT in 2009 and the JNU CEEB Fellowship in 2006 🎓.

Experience

Dr. Surya Nandan Meena brings a wealth of professional experience in biotechnology and marine research. Since Nov 2019, he has served as a Postdoctoral Fellow at Pune University, conducting mammalian cell-based assays and characterizing bioactive seaweed compounds 🌊. Earlier, at the National Institute of Oceanography (2017–2019), he surveyed 35+ seaweed species and contributed to multiple publications 📚. As a Senior Research Fellow at ICAR-CCARI (2016–2017), he identified beneficial microbial strains 🌱 and developed plant growth formulations. His roles also included mentoring students, publishing in high-impact journals, and leading interdisciplinary research, reflecting his dedication to scientific innovation and collaboration 👨‍🔬.

Research Focus

Dr. Surya Nandan Meena’s research centers on natural product chemistry, sustainable bioresource utilization, and drug discovery. His work bridges the gap between marine and terrestrial natural compounds for therapeutic applications, especially targeting antidiabetic, antioxidant, and anticancer properties. With notable contributions in biocatalysis, phytochemistry, and biosynthetic pathways, Dr. Meena emphasizes green, solvent-free synthesis and eco-friendly resource management. He actively explores seaweed farming, plant-based compounds, and essential oils as potent sources for novel bioactives. His multidisciplinary approach contributes significantly to natural compound-based drug development and sustainable healthcare innovation.

Publication Top Notes

Natural resources conservation and advances for sustainability

Graphite catalyzed solvent free synthesis of dihydropyrimidin-2 (1H)-ones/thiones and their antidiabetic activity

Seaweed Farming: A Perspective of Sustainable Agriculture and Socio-economic Development

Advances in Biological Science Research: A Practical Approach

Biosynthesis of vanillic acid by Ochrobactrum anthropi and its applications

α-Glucosidase inhibition activity and in silico study of 2-(benzo [d][1, 3] dioxol-5-yl)-4H-chromen-4-one, a synthetic derivative of flavone

Quick Identification of Piperidine Alkaloid from Roots of Grewia nervosa and Their Glucosidase Inhibitory Activity

Antioxidant and antiglycemic properties of macroalgae, an underutilized blue economy bioresource in India

Evaluation of silver-doped indium oxide nanoparticles as in vitro α-amylase and α-glucosidase inhibitors

New horizons in natural compound research

Biodegradation of seafood waste by seaweed-associated bacteria and application of seafood waste for ethanol production

Lior Zangi | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Lior Zangi | Drug Discovery and Development | Best Researcher Award

Prof. Lior Zangi, Icahn School of Medicine at Mount Sinai, United States

Prof. Lior Zangi is an Associate Professor of Cardiology and Genetics & Genomic Sciences at the Icahn School of Medicine at Mount Sinai, NY. He earned his Ph.D. in Immunology from the Weizmann Institute and completed postdoctoral training at Harvard Medical School. Renowned for his pioneering work in mRNA-based cardiovascular therapies, Prof. Zangi has received prestigious awards including the AHA Postdoctoral Fellowship and an endowed professorship in Cardiovascular Research. He is a founding board member of the Society for RNA Therapeutics and actively contributes to global scientific councils, manuscript reviews, and grant panels.

Publication Profile

Google Scholar

Education

Prof. Lior Zangi 🎓 began his academic journey with a B.Sc. in Biology from the Hebrew University, Givat-Ram, Jerusalem in 2000. He then earned his M.Sc. in Experimental and Developmental Medicine in 2003 from the Hebrew University Hadassah-Medical School under the guidance of Prof. Raphael Gorodetsky. In 2009, he completed his Ph.D. in Immunology at the Weizmann Institute of Science, mentored by Prof. Yair Reisner. 🌿 He continued his training as a postdoctoral fellow at Sheba Medical Center (2009–2010) under Prof. Benjamin Dekel and later at Harvard Medical School (2010–2014) with Professors Derrick Rossi and Kenneth Chien.

Awards

Prof. Lior Zangi 🌟 has earned numerous prestigious honors throughout his career. He received the ASH Travel Award in both 2008 and 2009 🧳, and in 2009, was granted a Postdoctoral Fellowship Award by the Israeli Budgeting Committee and Planning. In 2012, he was honored with both the ISSCR Travel Award and R&D Systems Travel Grant ✈️. His groundbreaking postdoctoral work earned him the AHA Fellowship Award in 2014 🫀. In 2017, he received the Mount Sinai Faculty Idea Prize 🧠, and in 2019, his research on mRNA therapy was recognized as highly influential 📜. In 2023, he was awarded the Endowed Chan Soon-Shiong Professorship in Cardiovascular Research 🏅.

Research Focus

Prof. Lior Zangi is a pioneering researcher in cardiovascular regenerative medicine, with a special focus on modified mRNA therapies, 🧬 stem cell biology, and 🫀 cardiac regeneration. His work centers on developing innovative strategies for repairing damaged heart tissue using modRNA, induced pluripotent stem cells (iPSCs), and heart-on-chip technologies. Zangi’s groundbreaking research has contributed to advancements in treating conditions like myocardial infarction and Barth syndrome, and has broad implications for tissue engineering, 💉 protein replacement therapy, and immune modulation. His contributions are reshaping modern precision medicine and offering new hope for heart failure patients worldwide.

Publication Top Notes

Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies

Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction

Isolation of mesenchymal stem cells from G-CSF-mobilized human peripheral blood using fibrin microbeads

Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells

A HCN4+ cardiomyogenic progenitor derived from the first heart field and human pluripotent stem cells

Isolation and characterization of nontubular sca-1+ lin− multipotent stem/progenitor cells from adult mouse kidney

Pkm2 regulates cardiomyocyte cell cycle and promotes cardiac regeneration

mRNA-based protein replacement therapy for the heart

Altering sphingolipid metabolism attenuates cell death and inflammatory response after myocardial infarction

Dr. Jonathan Myers| Clinical Trials|Best Researcher Award

Published on by Top Pharmaceutical

Dr.JonathanMyers|Clinical Trials|Best Researcher Award

Dr. Jonathan Myers at VA Palo Alto Health Care System,United States

PROFILE  

orcid

scopus

Summary 🎉

Dr. Jonathan Myers is a distinguished Clinical Professor of Medicine at Stanford University, celebrated for his extensive contributions to exercise physiology and cardiovascular health. With over four decades of experience in academia and clinical research, his work has significantly advanced the field, particularly in exercise testing and rehabilitation for patients with cardiovascular diseases.

Education 🎓

Dr. Myers began his academic journey with a Bachelor of Arts in Ergonomics and Physical Education from the University of California, Santa Barbara in 1980. He pursued a Master’s in Exercise Physiology at San Diego State University in 1982 and completed his PhD at the University of Southern California in 1991. His educational foundation has profoundly influenced his research and clinical practices.

Professional Experience 🏥

Dr. Myers has held various prestigious positions, including Clinical Professor at Stanford University since 2008. His role as a Research Career Scientist for the Veterans Administration since 2004 underscores his commitment to improving veterans’ lives through innovative rehabilitation strategies. He has also served as a Clinical Associate and Assistant Professor at Stanford and directed the Exercise Research Laboratory at the Long Beach Veterans Affairs Medical Center.

Contributions and Research Focus 🔬

Dr. Myers has made significant contributions to exercise physiology, particularly in cardiopulmonary exercise testing and cardiac rehabilitation. His research focuses on the physiological responses to exercise in various populations, including those with cardiovascular diseases, diabetes, and spinal cord injuries. He has played a key role in developing guidelines for exercise testing and prescription, influencing clinical practices globally.

Accolades and Recognition 🏆

Dr. Myers has received numerous awards, including the Citation Award from the American College of Sports Medicine (2021) and the Distinguished Professor Award from the Mexican Society of Cardiac Rehabilitation (2021). His accolades reflect his leadership and dedication to enhancing exercise science.

Impact and Influence 🌍

Dr. Myers’ influence extends beyond academia into public health and clinical practice. As a member of various organizations and committees, he has shaped policies advocating for the integration of exercise in healthcare. His involvement in the Healthy Living for Pandemic Event Protection (HL-PIVOT) Network emphasizes the importance of exercise in public health strategies.

Legacy and Future Contributions 🔮

Looking ahead, Dr. Myers aims to continue his research in exercise physiology, focusing on the needs of diverse populations, particularly in chronic diseases and rehabilitation. His dedication to mentorship and teaching will inspire the next generation of exercise physiologists. Dr. Myers remains committed to advocating for the critical role of physical activity in maintaining health and preventing disease, leaving a legacy of innovation and unwavering support for improving quality of life through exercise.

🎓Publication 

Impact of Cardiorespiratory Fitness on COVID-19–Related Outcomes: The Exercise Testing and Health Outcomes Study (ETHOS)

  • Authors   :Peter Kokkinos; Cristina Cadenas-Sanchez; Angelike Liappis; Carl J. Lavie; Navjit K. Goraya; Amy Weintrob; Andreas Pittaras; Alexandros Ladas
  • Journal    : Mayo Clinic Proceedings
  • Year         :2024

Analysis of Demographic and Socioeconomic Factors Influencing Adherence to a Web-Based Intervention Among Patients After Acute Coronary Syndrome: Prospective Observational Cohort Study (Preprint)

  • Authors   :Biagio Sassone; Giuseppe Fuca’; Mario Pedaci; Roberta Lugli; Enrico Bertagnin; Santo Virzi’; Manuela Bovina; Giovanni Pasanisi; Simona Mandini; Jonathan 
  • Journal    :Preprint
  • Year         :2024

 

Hypertension and Ventilatory Responses During Exercise in the Fitness Registry and the Importance of Exercise National Database (FRIEND)

  • Authors   :  Joseph C. Watso; Austin T. Robinson; Ross Arena; Matthew P. Harber; Leonard A. Kaminsky; Jonathan Myers
  • Journal    :The Journal of Infection in Developing Countries
  • Year         :2024

Analysis of Demographic and Socioeconomic Factors Influencing Adherence to a Web-Based Intervention Among Patients After Acute Coronary Syndrome: Prospective Observational Cohort Study

  • Authors   : Biagio Sassone; Giuseppe Fuca’; Mario Pedaci; Roberta Lugli; Enrico Bertagnin; Santo Virzi’; Manuela Bovina; Giovanni Pasanisi; Simona Mandini; Jonathan
  • Journal    :JMIR Cardio
  • Year         :2024

Dr. ANTHOULA LAZARIS| Precision Medicine|Best Researcher Award

Published on by Top Pharmaceutical

Dr. ANTHOULA LAZARIS, Precision Medicine,Best Researcher Award

Dr. ANTHOULA LAZARIS, at MCGILL UNIV. HEALTH CTR,Canada

PROFILE

scopus

📚 Early Academic Pursuits :

Anthoula Lazaris began her academic journey with a B.Sc. in Microbiology and Immunology from McGill University (1983-1986), where she developed a solid foundation in the biological sciences. She continued at McGill, earning a Ph.D. in Biochemistry from the Faculty of Medicine (1988-1992). Her postdoctoral studies took her to Leiden, The Netherlands, where she further honed her expertise in Medical Biochemistry (1992-1994). This robust educational background laid the groundwork for her illustrious career in academia and biotechnology.

🏢Professional Endeavors :

Lazaris has accumulated over 30 years of combined experience in academia and industry, holding management and senior-level positions. Currently, she is a scientist at the Research Institute of the McGill University Health Centre (RI-MUHC), focusing on metastatic and metabolic diseases with an emphasis on translational research. Her career highlights include:

  • Liver Disease Biobank: In 2011, Lazaris established a Liver Disease Biobank in collaboration with Dr. P Metrakos, collecting biospecimens from patients with liver-related diseases.
  • Quebec Extracellular Vesicle Consortium: She spearheaded this consortium with Drs. Rak and Olivier, demonstrating her leadership in collaborative research initiatives.
  • CIHR Training Grant: Lazaris co-wrote and secured a substantial CIHR training grant for the Goodman Cancer Centre, illustrating her proficiency in obtaining competitive funding.

🔬Contributions and Research Focus :

Lazaris’s research contributions span several critical areas:

  • Metastatic Disease: She focuses on colorectal cancer liver metastases (CRCLM), investigating molecular mechanisms to predict therapeutic responses and developing new biomarkers.
  • Translational Research: Her work bridges basic and clinical research, aiming to translate findings into precision therapies for cancer patients. Notably, her research on predictors of therapeutic responses to antiangiogenic agents has been groundbreaking.
  • Liver Diseases: Lazaris’s research also covers hepatocellular carcinoma, cholangiocarcinomas, and NAFLD/NASH, contributing to the broader understanding of these conditions.

🏆Accolades and Recognition :

Throughout her career, Lazaris has received numerous accolades:

  • Scientific American Award: In 2002, she was recognized in the category of Research Leader in Chemical and Materials for her work on transgenic animals producing spider silk.
  • Genome Canada White Paper: She spearheaded the writing of a white paper on “Disease Mechanisms,” which was integrated into Genome Quebec’s strategic plan.
  • Scientific Publications: Her research has been published in prestigious journals like Nature and Science, highlighting her contributions to molecular biology and oncology.

🌍Impact and Influence :

Lazaris’s work has had a profound impact on both the scientific community and public health:

  • Innovations in Biotechnology: She was part of the team that demonstrated the first expression of soluble spider silk, which can be spun into fibers with remarkable mechanical properties.
  • Transgenic Research Network: As the Executive Director of the Quebec Transgenic Research Network, Lazaris unified the capabilities of researchers across Quebec, securing significant funding and fostering collaborative research.
  • Cloned Animals: She was part of the team that generated the world’s first cloned goat and Canada’s first large transgenic animal, showcasing her pioneering contributions to genetic engineering.

🌟Legacy and Future Contributions :

Anthoula Lazaris’s legacy is marked by her pioneering research, leadership in collaborative scientific endeavors, and significant contributions to translational medicine. Her work continues to influence the fields of molecular biology, biotechnology, and cancer research. Looking forward, Lazaris is expected to further her contributions to personalized medicine, leveraging her extensive experience and innovative approach to address pressing challenges in healthcare. Her dedication to translational research and collaborative spirit ensures that her impact will be felt for years to come.

🎓Publication 

Predictive biomarker discovery in cancer using a unique AI model based on set theory

Hepatic stellate cell stearoyl co-A desaturase activates leukotriene B4 receptor 2 – β-catenin cascade to promote liver tumorigenesis

    • Authors :Sinha, S., Aizawa, S., Nakano, Y., … Guccione, E., Tsukamoto, H.
    • Journal   :Nature Communications
    • Year       : 2023

Targeting Liver Metastases to Potentiate Immunotherapy in MS-Stable Colorectal Cancer—A Review of the Literature

  • Authors  :, Zlotnik, O., Krzywon, L., Bloom, J., … Lazaris, A., Metrakos, P.
  • Journal    :Cancers
  • Year         :  2023

Isolation of extracellular vesicles from human plasma samples: The importance of controls

  • Authors  :Tsamchoe, M., Petrillo, S., Lazaris, A., Metrakos, P.
  • Journal   : Biotechnology Journal
  • Year        :   2023

A Retrospective Study on the Role of Metformin in Colorectal Cancer Liver Metastases

  • Authors  :Rada, M., Krzywon, L., Petrillo, S., Lazaris, A., Metrakos, P.
  • Journal   : Biotechnology 
  • Year        :  2023